Advicenne Announces Commercialization Agreement with FrostPharma AB for Sibnayal in the Nordic Region

Advicenne will receive a transfer price and royalties for an amount markedly higher than 50% of future sales of Sibnayal - Sibnayal will be marketed to one-third of European patients by three members

Related Keywords

Norway ,Finland ,Sweden ,Iceland ,Paris ,France General ,France ,Denmark ,United Kingdom ,Swedish ,Ashley Tapp ,Mary Jane Elliott ,Davide Salvi ,Advicenne Euronext ,Didier Laurens ,French Financial Markets Authority Autorit ,European Commission ,Head Of Business Development Frostpharma ,Early Access Program ,Consilium Strategic Communications ,Pharma Partner ,Eastern European ,Chief Executive Officer ,Business Development ,Distal Renal Tubular Acidosis ,Marketing Approval ,Euronext Paris ,Euronext Brussels ,Eastern Europe ,French Financial Markets Authority ,General Regulation ,Jane Elliott ,Advicenne ,Nnounces ,Ommercialization ,Agreement ,Rostpharma ,Ibnayal ,Ordic ,Region ,